Refine by
Brain Disorder Articles & Analysis
38 news found
This comprehensive collection provides researchers with a unique resource to study various neurological conditions and accelerate their investigations into neurological diseases and disorders. CD Bioscience has been developing imaging technologies for many years and uses high content imaging, nanoparticle imaging, imaging flow cytometry, time-lapse imaging and other technologies ...
He is also executive chairman of Cordance Medical, a company revolutionizing treatment of cancer, Alzheimer’s disease, and other brain disorders using non-invasive transcranial focused ultrasound to temporarily open the blood-brain-barrier. ...
ByElucid
Cerebral Therapeutics is combining advanced micro-dosing technology with proprietary medications to precisely deliver treatments to the other side of the blood-brain barrier to improve the lives of patients with uncontrolled neurological disease. With a promising route of administration, Cerebral Therapeutics offers a new approach to managing neurological diseases by means of ...
Research reported in this publication was supported by the National Institute Of Neurological Disorders And Stroke (NINDS) of the National Institutes of Health (NIH) under Award Number R42NS120548. ...
” Although stroke is the most common cause, aphasia can also occur due to traumatic brain injury or neurodegenerative disorders. There are two main types of aphasia. ...
ByBioMedSA
Even more noteworthy, results from the studies revealed that KLS-13019 did not bind to opioid receptors in the brain, meaning it holds a very low risk for chemical dependency. “Following our recent grant award from the National Institute of Health – National Institute of Neurological Disorders and Stroke (NIH-NINDS), under the HEAL initiative, these ...
-Shareholder-Letter-220406.pdf Research reported in this publication was supported by the National Institute Of Neurological Disorders And Stroke (NINDS) of the National Institutes of Health (NIH) under Award Number R42NS120548. ...
The presentation titled, “Gut-Brain Axis: How substances produced by the microbiome may contribute to Autism Spectrum Disorder,” will be held on Saturday, April 9 from 1:00-2:00 pm PST. ...
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it is expanding its strategic supplier partnership with leading gradient index (GRIN) lens manufacturer GRINTECH GmbH to be the sole exclusive seller of GRIN lenses for neuroscience research applications. ...
With the Inscopix platform now able to perform blood flow and neuronal imaging studies simultaneously within deep brain regions over months, researchers will have unprecedented access to study the underpinnings of neurodegenerative and neurological disorders. ...
The Company was recently awarded a three-year $2.97 million Phase 2 STTR Study Grant by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). ...
For complete survey methodology, including weighting variables and subgroup sample sizes, or for any additional questions regarding the survey, please send requests to mediainfo@alkermes.com. About Bipolar I Disorder Bipolar disorder is a brain disorder that is marked by extreme changes in a person's mood, energy and ability ...
ByAlkermes
The company built a digital platform that applies real-time AI to wearable electroencephalograms (EEG) to externalize brain state changes that provide real-time digital interventions to reduce the daily life impact of a brain disorder and to generate real-world data for better treatments. ...
About KLS-13019 KLS-13019 is Neuropathix patented lead clinical target for the potential treatment of a range of neurotoxic, neurodegenerative and neuropathic pain disorders, beginning with CIPN. KLS-13019 is a monotherapeutic non-opioid cannabinoid derivative that has been shown to prevent and reverse neuropathic pain in pre-clinical animal studies. ...
(“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, today announces that its wholly owned subsidiary, Kannalife Sciences, Inc. has received a notice of award from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) for a $2.97 million Phase 2 ...
We now move into the commercial phase of development for LEA™ and, as such, we have now formed Dermique to capitalize on LEA™ as well as the underlying brands we intend to bring to the market for a variety of disorders and skin problems. Our preclinical studies have demonstrated, alongside certain isolated test subjects, that LEA™ is simply better than CBD for ...
For the August installment of the Healthtech Leader of the Month series, we interviewed Aswin Gunasekar, founder and CEO of Zeto. Zeto is a device-driven platform for acquiring, accessing, and interpreting electroencephalograms (EEGs). An EEG is a test used to evaluate electrical activity in the ...
WO/2021/097351 “Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Radiation Dermatitis and Other Skin Disorders.” One of the compounds disclosed as part of this PCT Patent is the Company’s proprietary ingredient LEA™. ...
Electroencephalography (EEG) devices are incredibly helpful in diagnosing and monitoring certain brain disorders, such as epilepsy and strokes. However, they are not particularly user-friendly or convenient, with specialized technicians performing time consuming procedures, such as skin preparation, to get patients ready to undergo the procedure. ...
A press release states that EEG (electroencephalogram) tests are conducted to detect problems in the brain that may be associated with certain brain disorders such as seizures, tumors or strokes. ...